Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

Unravelling species barriers of coronaviruses

Objective

"Human coronaviruses (CoVs) are distributed worldwide and cause a significant percentage of all common colds. Most of these viruses presumably emerged through zoonotic transmission, have adapted to the human host, and are now known to cause mild upper respiratory tract infections. However, the more recent zoonotic transmission of the highly pathogenic Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) have demonstrated the potential of coronaviruses to also cause highly severe human diseases and are associated with a high mortality. The precise mechanisms that allow coronaviruses to jump across species barriers are only poorly understood. ""COV RESTRIC"" aims to unravel species barriers of coronavirus infections and to uncover basic host cell mechanisms preventing a transmission across different species. We hypothesize that conserved restriction factors exist between different species which limit viral replication and which need to be overcome via viral evasion and adaptation strategies in order to establish a zoonotic infection. These may include the lack or genetic incompatibility of essential viral replication co-factors as well as the presence of antiviral restriction mechanisms. We will use two complementary genetic screening approaches to identify unknown coronavirus restriction factors. Once we have identified possible candidates, we will analyze them for their cross-conservation employing coronaviruses from different species, such as human, bat and camel virus isolates, as well as the respective primary cell culture material originating from the authentic host. This approach will help to rigorously define species barriers to viral transmission which should promote future development of preventive and therapeutic strategies to combat emerging RNA virus infections in humans."

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

MSCA-IF-EF-SE - Society and Enterprise panel

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) H2020-MSCA-IF-2016

See all projects funded under this call

Coordinator

EIDGENOESSISCHES DEPARTEMENT DES INNERN
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 187 419,60
Address
Inselgasse 1
3003 Bern
Switzerland

See on map

Region
Schweiz/Suisse/Svizzera Espace Mittelland Bern / Berne
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 187 419,60
My booklet 0 0